
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
Beauty Health's fourth-quarter revenue of $96.8 million exceeded both internal estimates and broader market expectations, indicating robust demand for its products, particularly consumables. The average selling price (ASP) for total systems increased approximately 20% quarter-over-quarter to $28.8K, significantly surpassing earlier projections, driven by a higher percentage of direct sales as opposed to distributor orders. Although EBITDA guidance remains back-end weighted, the overall revenue performance and strong ASP growth underscore a positive trajectory for the company's financial health.
Bears say
Beauty Health Co. is facing significant challenges, with core delivery system placements declining over 30% year-over-year and quarter-over-quarter, falling short of previous expectations. This deceleration in new system placements raises concerns about future consumables sales, which are critical for reaching profitability goals in 2024. Additionally, management's first-quarter guidance for sales and adjusted EBITDA indicates expectations that are substantially below prior estimates, contributing to a negative outlook on the company's financial health.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares